CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two virtual investor conferences in December 2021. The first event is the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 12:35 p.m. ET. The second is the Piper Sandler 33rd Annual Healthcare Conference on December 2, 2021, at 1:00 p.m. ET. Webcast access will be available on CRISPR's website, with replays archived for 14 days post-event. CRISPR is focused on developing transformative gene-based medicines using its CRISPR/Cas9 platform.

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in December:

4th Annual Evercore ISI HealthCONx Conference
Date: Wednesday, December 1, 2021
Time: 12:35 p.m. ET

Piper Sandler 33rd Annual Healthcare Conference
Date: Thursday, December 2, 2021
Time: 1:00 p.m. ET

A live webcast of the events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following each presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS^® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com

FAQ

What events will CRISPR Therapeutics participate in during December 2021?

CRISPR Therapeutics will participate in the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, and the Piper Sandler 33rd Annual Healthcare Conference on December 2, 2021.

What is the time for CRISPR Therapeutics appearances at the investor conferences?

CRISPR Therapeutics will present at the Evercore ISI HealthCONx Conference at 12:35 p.m. ET on December 1, 2021, and at the Piper Sandler Healthcare Conference at 1:00 p.m. ET on December 2, 2021.

Where can I find the webcast for CRISPR Therapeutics' investor conferences?

The webcast for CRISPR Therapeutics' investor conferences will be available on the 'Events & Presentations' page of their website.

How long will the webcasts be available for replay after the conferences?

The webcasts will be archived on CRISPR Therapeutics' website for 14 days following each presentation.

What is the main focus of CRISPR Therapeutics as a company?

CRISPR Therapeutics focuses on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 technology.